For decades, patients diagnosed with IgA nephropathy—an autoimmune condition where trapped immune complexes inflame and damage the kidney’s filtering units (glomeruli)—faced a discouraging outlook. Typically diagnosed in young adults aged in their 20s or 30s, the disease often resulted in kidney failure and a dependence on dialysis within their lifetime due to a lack of effective treatments beyond traditional, often unsuccessful, steroid therapies.
Between 2024 and 2026, Dana Rizk, M.D., professor in UAB’s Division of Nephrology, co-led four groundbreaking Phase 3 clinical trials that drastically shifted how this condition is managed, offering patients multiple targeted therapeutic options.
Key Breakthroughs & Approved Therapies
Rather than offering cures, these new therapies significantly slow disease progression, delaying the need for dialysis by decades and improving quality of life. Three major therapies received accelerated approval from the U.S. Food and Drug Administration (FDA):
- Iptacopan (Fabhalta) — APPLAUSE-IgAN Trial
- Mechanism: Inhibits the immune system’s alternative complement pathway.
- Impact: Reduced proteinuria (protein in urine) by 38.3% and roughly halved the rate of annual kidney function loss. Approved in 2024.
- Sibeprenlimab-szsi (Voyxact) — VISIONARY Trial
- Mechanism: First approved therapy targeting APRIL, a protein influencing IgA production in B cells.
- Impact: Achieved a 50% reduction in proteinuria compared to a 2% reduction in placebo groups. Approved in November 2025.
- Atacicept (Trutakna) — ORIGIN 3 Trial
- Mechanism: Dual-targets both APRIL and BAFF proteins to reduce IgA production across a broader B-cell population.
- Impact: Delivered a 45.7% decrease in baseline proteinuria. Approved in July 2026.
How the Research Pipeline Accelerated
The breakthrough stemmed from two vital factors:
- Basic Science Foundation: Long-term collaborative research between UAB faculty members Jan Novak, Ph.D., Bruce Julian, M.D., and Dr. Rizk pinpointed the precise molecular pathways of the disease, supplying pharmaceutical developers with specific targets.
- Innovative Trial Models: Through the Kidney Health Initiative (a partnership between the FDA and the American Society of Nephrology), researchers revolutionized clinical trial frameworks. Instead of waiting years for traditional “hard endpoints” (transplant, dialysis, or death), the FDA accepted significant reductions in proteinuria as an intermediate surrogate marker for accelerated drug approval.
Impact on Patient Care and Future Directions
These advancements are directly benefiting patients at UAB’s Glomerular Disease Clinic, which attracts individuals from across Alabama and surrounding states seeking cutting-edge care and clinical trial access.
Looking forward, researchers aim to expand these therapies to:
- Pediatric patients (who currently lack effective options).
- Patients in earlier stages of IgA nephropathy.
- Other rare kidney conditions and broader autoimmune disorders.
Training the Next Generation of Clinical Researchers
To address a historic shortage of trials in nephrology, UAB is leveraging this momentum to train future clinician-scientists:
- Leadership Role: In 2025, Dr. Rizk was appointed Associate Dean for Clinical Trials at the UAB Heersink School of Medicine.
- Development Program: In 2026, alongside David Kimberlin, M.D., Dr. Rizk co-led UAB’s Clinical Trialist Development Program.
- Goal: Expand the university’s trialist workforce, attract industry-sponsored trials, and bring novel medical breakthroughs to Alabama patients faster.
